Clinical Trial

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Study acronym: ZUMA-23
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-16
notable Trial sites reduced: 90 -> 85 locations 2026-04-16
Trial Details
NCT Number NCT05605899
Lead Sponsor Kite, A Gilead Company
Conditions High-risk Large B-cell Lymphoma (LBCL)
Enrollment 300 participants
Start Date 2023-02-10
Primary Completion 2031-03 (estimated)
Study Completion 2031-03 (estimated)
Updated on ClinicalTrials.gov 2026-04-15